Trial Profile

A Phase Ib/II, Open-label, Multicenter Clinical Study to Evaluate the Antitumor Activities, Safety, and Tolerability of IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Ifebemtinib (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors InxMed

02 May 2025 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results (n=26; At data cutoff of April 28, 2023) assessing the safety and antitumor activity of IN10018 combined with toripalimab in metastatic triple-negative breast cancer, presented at the 48th European Society for Medical Oncology Congress.
28 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com